Mesenchymal stem cell therapy for diabetic nephropathy - Medipost
Alternative Names: SMUP-IV-01Latest Information Update: 30 Mar 2023
At a glance
- Originator Medipost
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Diabetic nephropathies
Most Recent Events
- 30 Mar 2023 Preclinical trials in diabetic nephropathies in South Korea (IV) (Medipost pipeline, March 2023)